RU2004111359A - Комбинированные агенты для лечения глаукомы - Google Patents

Комбинированные агенты для лечения глаукомы Download PDF

Info

Publication number
RU2004111359A
RU2004111359A RU2004111359/15A RU2004111359A RU2004111359A RU 2004111359 A RU2004111359 A RU 2004111359A RU 2004111359/15 A RU2004111359/15 A RU 2004111359/15A RU 2004111359 A RU2004111359 A RU 2004111359A RU 2004111359 A RU2004111359 A RU 2004111359A
Authority
RU
Russia
Prior art keywords
treatment
glaucoma
prevention
active ingredients
combination
Prior art date
Application number
RU2004111359/15A
Other languages
English (en)
Inventor
Томихиса ЙОКОЯМА (JP)
Томихиса ЙОКОЯМА
Original Assignee
Санкио Компани, Лимитед (Jp)
Санкио Компани, Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санкио Компани, Лимитед (Jp), Санкио Компани, Лимитед filed Critical Санкио Компани, Лимитед (Jp)
Publication of RU2004111359A publication Critical patent/RU2004111359A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Claims (3)

1. Комбинация для профилактики или лечения глаукомы, которая включает антагонист ангиотензина II и тимолол малеат в качестве активных ингредиентов, для одновременного, раздельного или последовательного использования указанных активных ингредиентов, где антагонист ангиотензина II представляет собой соединение формулы (I) или его фармакологически приемлемую соль, сложный эфир или другое производное:
Figure 00000001
где R1 представляет группу, имеющую структурную формулу (Ia):
Figure 00000002
2. Комбинация для профилактики или лечения глаукомы по п. 1, которая находится в форме, удобной для местного нанесения в глаза.
3. Способ профилактики или лечения глаукомы, который включает введение пациенту комбинации для профилактики или лечения глаукомы по п.1 или 2.
RU2004111359/15A 1999-12-01 2004-04-13 Комбинированные агенты для лечения глаукомы RU2004111359A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP11/341524 1999-12-01
JP34152499 1999-12-01
JP2000078769 2000-03-21
JP2000-78769 2000-03-21

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2002114335/15A Division RU2002114335A (ru) 1999-12-01 2000-12-01 Комбинированные агенты для лечения глаукомы

Publications (1)

Publication Number Publication Date
RU2004111359A true RU2004111359A (ru) 2005-09-20

Family

ID=26576988

Family Applications (4)

Application Number Title Priority Date Filing Date
RU2002114335/15A RU2002114335A (ru) 1999-12-01 2000-12-01 Комбинированные агенты для лечения глаукомы
RU2004111357/15A RU2299067C2 (ru) 1999-12-01 2004-04-13 Комбинированные агенты для лечения глаукомы
RU2004111359/15A RU2004111359A (ru) 1999-12-01 2004-04-13 Комбинированные агенты для лечения глаукомы
RU2004111358/15A RU2004111358A (ru) 1999-12-01 2004-04-13 Комбинированные агенты для лечения глаукомы

Family Applications Before (2)

Application Number Title Priority Date Filing Date
RU2002114335/15A RU2002114335A (ru) 1999-12-01 2000-12-01 Комбинированные агенты для лечения глаукомы
RU2004111357/15A RU2299067C2 (ru) 1999-12-01 2004-04-13 Комбинированные агенты для лечения глаукомы

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2004111358/15A RU2004111358A (ru) 1999-12-01 2004-04-13 Комбинированные агенты для лечения глаукомы

Country Status (22)

Country Link
US (4) US7307096B2 (ru)
EP (3) EP1344535A3 (ru)
JP (1) JP4000505B2 (ru)
KR (3) KR20040045028A (ru)
CN (3) CN1615879A (ru)
AT (1) ATE332145T1 (ru)
AU (1) AU773110B2 (ru)
BR (1) BR0015980A (ru)
CA (1) CA2392804C (ru)
CZ (1) CZ20021829A3 (ru)
DE (1) DE60029242T2 (ru)
ES (1) ES2267586T3 (ru)
HK (1) HK1047239B (ru)
HU (1) HUP0204049A3 (ru)
IL (2) IL149444A0 (ru)
MX (1) MXPA02005505A (ru)
NO (1) NO20022584L (ru)
NZ (1) NZ518930A (ru)
PL (1) PL201783B1 (ru)
RU (4) RU2002114335A (ru)
TW (1) TWI290470B (ru)
WO (1) WO2001039805A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0209063A (pt) * 2001-04-19 2004-08-10 Teika Pharmaceutical Co Ltd Medicamentos e kits de uso medicinal
TW200305424A (en) 2002-01-29 2003-11-01 Santen Pharmaceutical Co Ltd Glaucoma-treating agent comprising bunazosin and prostaglandin
US20050119299A1 (en) * 2002-03-08 2005-06-02 Sankyo Company, Limited Ophthalmic solutions containing tetrazole derivatives
US8580851B2 (en) 2002-08-21 2013-11-12 Sucampo Ag Ophthalmic solution
WO2005018646A1 (ja) * 2003-08-21 2005-03-03 Sucampo Ag 眼科用組成物
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
WO2005079809A1 (ja) * 2004-02-19 2005-09-01 Santen Pharmaceutical Co., Ltd. 澄明なラタノプロスト点眼液
JP2005263792A (ja) * 2004-02-19 2005-09-29 Santen Pharmaceut Co Ltd 澄明なラタノプロスト点眼液
CN103768070A (zh) * 2006-03-13 2014-05-07 株式会社·R-技术上野 水性组合物
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
WO2011138801A1 (en) * 2010-05-07 2011-11-10 Sun Pharma Advanced Research Company Ltd. Novel ophthalmic compositions
RU2443416C2 (ru) * 2010-05-17 2012-02-27 Республиканское Унитарное производственное предприятие "Белмедпрепараты" Капли глазные
JP6023082B2 (ja) * 2011-01-24 2016-11-09 インセプタム リサーチ アンド セラピューティクス,インク. 精神神経性の疾病を処置するためのプロスタグランジンを含む組成物
KR101327267B1 (ko) 2012-04-26 2013-11-11 한양대학교 에리카산학협력단 엔드이펙터용 구동력 전달장치
KR102511830B1 (ko) 2014-11-25 2023-03-17 엑시모어 엘티디. 단일 및 다수 생체활성제를 전달하기 위한 조성물 및 방법
CA2970275A1 (en) * 2014-12-12 2016-06-16 Kowa Company, Ltd. Aqueous composition

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3619370A (en) 1969-04-21 1971-11-09 Frosst & Co Charles E Microbial reduction of thiadiazoles
JPS536156B2 (ru) 1972-10-30 1978-03-04
IE50901B1 (en) * 1980-03-04 1986-08-06 Merck & Co Inc Ophthalmic compositions of carbonic anhydrase inhibitors for topical application in the treatment of elevated intraocular pressure
US4394382A (en) 1980-06-17 1983-07-19 Kowa Company, Ltd. Dihydrobenzopyran compounds and pharmaceutical composition comprising said compounds
ATE41002T1 (de) * 1984-12-12 1989-03-15 Merck & Co Inc Substituierte aromatische sulfonamide, ihre herstellung und diese enthaltende ophthalmische zubereitungen.
US4863922A (en) 1984-12-12 1989-09-05 Merck & Co., Inc. Substituted aromatic sulfonamides as antiglaucoma agents, compositions and use
US5182264A (en) * 1986-03-07 1993-01-26 Schering Corporation Angiotensin II receptor blockers as antiglaucoma agents
JP2610619B2 (ja) * 1987-07-22 1997-05-14 エーザイ株式会社 高眼圧症治療用点眼剤
JPS6426518U (ru) 1987-08-11 1989-02-15
JP2721414B2 (ja) 1988-09-06 1998-03-04 フアーマシア・アンド・アツプジヨン・アー・ベー 縁内障または眼圧亢進の治療のためのプロスタグランジン誘導体
DE58908744D1 (de) 1988-09-09 1995-01-19 Draenert Klaus Hüftgelenksprothese und ihre verwendung.
EP0375299A1 (en) * 1988-12-19 1990-06-27 Merck & Co. Inc. Combinations of angiotensin converting enzyme, and carbonic anhydrase, inhibitors for treating glaucoma
US5273976A (en) * 1989-04-06 1993-12-28 Sankyo Company, Limited Ocular hypotensive agents
US5175161A (en) * 1989-04-06 1992-12-29 Sankyo Company, Limited Occular hypotensive agents
WO1991015206A1 (en) * 1990-04-05 1991-10-17 E.I. Du Pont De Nemours And Company Treatment of glaucoma and ocular hypertension with imidazole angiotensin-ii receptor antagonists
US5250521A (en) 1990-12-07 1993-10-05 Merck & Co., Inc. Substituted pyrazolopyrimidines as angiotensin II antagonists
CA2057089A1 (en) * 1990-12-07 1992-06-08 Eric E. Allen Substituted pyrazolopyrimidines and imidazopyridazines as angiotensin ii antagonists
NZ242724A (en) * 1991-05-15 1994-09-27 Du Pont Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
IL104648A0 (en) 1992-02-13 1993-06-10 Merck & Co Inc Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a prostaglandin or prostaglandin derivative
WO1993016701A2 (en) * 1992-02-21 1993-09-02 Alcon Laboratories, Inc. Topical antiglaucoma compositions comprising carbonic anhydrase inhibitors and beta-blockers
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
CZ154994A3 (en) * 1993-07-02 1995-09-13 Senju Pharma Co Visual hypotensive agent
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
AU1423795A (en) * 1994-02-08 1995-08-29 Novartis Ag Treatment of normotensive glaucoma with angiotensin ii antagonists
HUT74734A (en) 1994-03-16 1997-02-28 Sankyo Co Use of biphenyl methyl imidazole derivatives for producing pharmaceutical compositions having ocular tension derpessant activity
CA2185524C (en) * 1994-03-16 2006-12-05 Tomihisa Yokoyama Ocular tension depressant
US5760249A (en) * 1995-08-29 1998-06-02 Merck & Co., Inc. Synthesis of hydroxysulfone and related compounds
US5741810A (en) 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
CN1215338A (zh) * 1996-04-05 1999-04-28 武田药品工业株式会社 包含具有血管紧张素ⅱ拮抗活性的化合物的药物组合物
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
CA2293325C (en) 1997-05-09 2008-09-02 The Mount Sinai School Of Medicine Of The City University Of New York 8-iso-prostaglandins for glaucoma therapy
HUP0201466A3 (en) * 1999-06-11 2003-04-28 Sankyo Co Ocular tension lowering composition for topical administration

Also Published As

Publication number Publication date
ATE332145T1 (de) 2006-07-15
HK1047239B (zh) 2006-12-08
DE60029242T2 (de) 2007-07-05
EP1344534A2 (en) 2003-09-17
EP1234582B1 (en) 2006-07-05
HUP0204049A3 (en) 2006-07-28
NO20022584L (no) 2002-07-29
EP1344535A3 (en) 2004-01-28
RU2004111357A (ru) 2005-09-20
NZ518930A (en) 2003-09-26
KR20040045029A (ko) 2004-05-31
CN1407903A (zh) 2003-04-02
TWI290470B (en) 2007-12-01
US20080221184A1 (en) 2008-09-11
IL149444A0 (en) 2002-11-10
CZ20021829A3 (cs) 2002-08-14
CN1615880A (zh) 2005-05-18
KR100607430B1 (ko) 2006-08-02
HUP0204049A2 (hu) 2003-04-28
BR0015980A (pt) 2002-11-12
RU2004111358A (ru) 2005-09-20
AU1557501A (en) 2001-06-12
CA2392804A1 (en) 2001-06-07
ES2267586T3 (es) 2007-03-16
EP1234582A1 (en) 2002-08-28
CA2392804C (en) 2009-02-03
EP1234582A4 (en) 2003-05-07
KR20040045028A (ko) 2004-05-31
DE60029242D1 (de) 2006-08-17
RU2299067C2 (ru) 2007-05-20
RU2002114335A (ru) 2004-01-10
EP1344535A2 (en) 2003-09-17
PL201783B1 (pl) 2009-05-29
US20050014808A1 (en) 2005-01-20
US20050043383A1 (en) 2005-02-24
AU773110B2 (en) 2004-05-20
JP4000505B2 (ja) 2007-10-31
HK1047239A1 (en) 2003-02-14
WO2001039805A1 (fr) 2001-06-07
JP2001335511A (ja) 2001-12-04
CN1615879A (zh) 2005-05-18
IL149444A (en) 2007-06-17
MXPA02005505A (es) 2002-09-02
NO20022584D0 (no) 2002-05-31
CN1263512C (zh) 2006-07-12
US7307096B2 (en) 2007-12-11
EP1344534A3 (en) 2004-01-02
PL355431A1 (en) 2004-04-19
KR20020058034A (ko) 2002-07-12
US20030040529A1 (en) 2003-02-27

Similar Documents

Publication Publication Date Title
RU2004111359A (ru) Комбинированные агенты для лечения глаукомы
KR101092048B1 (ko) Rho 키나아제 억제제 및 프로스타글란딘류를 포함하는녹내장 치료제
JP4934653B2 (ja) Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
LU92058I2 (fr) Travoprost et ses sels pharmaceutiquement acceptables (TRAVATAN®)
CA2188164A1 (en) Benzamide compounds and pharmaceutical use thereof
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
DK0668863T3 (da) Quinuclidinderivat som substans P-antagonist
RU2003130058A (ru) Комбинации, включающие антидиарейный агент и эпотилон или производные эпотилона
IL149496A (en) Pharmaceutical compositions and their use in the treatment of the gastrointestinal tract
LV12291A (lv) Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai
RU2002117649A (ru) Фармацевтические композиции, содержащие золмитриптан
CA2378613A1 (en) Selective iglur5 receptor antagonists for the treatment of migraine
SE0102055D0 (sv) New Compounds
RU2000122435A (ru) Производные индола и фармацевтические композиции, включающие их
DK1458393T3 (da) Substituerede diketopiperaziner som oxytocinantagonister
JP2004107335A (ja) Rhoキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
EA200301203A1 (ru) Новые соединения и композиции как ингибиторы катепсина
RU2209064C2 (ru) Новое применение в медицинских целях
KR960034190A (ko) N-아실피페라진 유도체 및 항균제, 항궤양제
RU2227740C2 (ru) Композиции, снижающие внутриглазное давление, для местного применения
SE9401087D0 (sv) New prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
RU2004129767A (ru) Хинолиновые производные
WO2005021040A3 (en) Compositions useful for treating gastrointestinal motility disorders
CZ378597A3 (cs) Použití derivátů pyrrolidinu k léčení alkoholismu
WO2019124523A1 (ja) FP作動薬とβ遮断薬を含有する緑内障治療剤

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20060418